

INSIDE THIS ISSUE

- [Editor's Choice – Highlights of Changes in Protocols, Pre-Printed Orders and Patient Handouts](#) – Gastrointestinal Tumour Group: Palliative Treatment of Advanced Gastric and Esophagogastric Cancers
 - [List of New and Revised Protocols, Pre-Printed Orders and Patient Handouts](#): **New:** GIA, GIIR, GIIRINALT, GIPAJGEM, GIPGEM, GIRALT,
 - [Website Resources](#)
- UMYLENDEX **Revised:** UBRAVABR, GIGAVECC, GIGAVECF, GOCXCRT, HNDE, HNLANPRT, HNM, LYHDMRP, LYHDMTXP, LYHDMTXR
- IN TOUCH phone list is provided if additional information is needed.

EDITOR'S CHOICE:

HIGHLIGHTS OF CHANGES IN PROTOCOLS, PRE-PRINTED ORDERS AND PATIENT HANDOUTS

The **Gastrointestinal Tumour Group** has removed the requirement for CAP approval (BCCA Compassionate Access Program) for GIGAVECC and GIGAVECF. These two protocols are used as **palliative treatment of metastatic or locally advanced gastric or esophagogastric cancer**. For GIGAVECC, capecitabine is now a class II benefit indication.

The Tumour Group has also developed **six new information handouts** for patients undergoing chemotherapy. The patient handouts match existing treatment protocols GIA, GIIR, GIIRINALT, GIPAJGEM, GIPGEM, GIRALT.

LIST OF NEW AND REVISED PROTOCOLS, PRE-PRINTED ORDERS AND PATIENT HANDOUTS

BC Cancer Agency Protocol Summaries, Provincial Pre-Printed Orders (PPPOs) and Patient Handouts are revised periodically. New and revised protocols, PPPOs and patient handouts for this month are listed below. Protocol codes for treatments requiring "Compassionate Access Program" (previously Undesignated Indication Request) approval are prefixed with the letter **U**.

NEW PROTOCOLS, PPPOs AND PATIENT HANDOUTS (AFFECTED DOCUMENTS ARE CHECKED):

CODE	Protocol	PPPO	Patient Handout	Protocol Title
GIA	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	Palliative Chemotherapy for Cancer of the Liver (Hepatoma) Using Doxorubicin
GIIR	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	Palliative Chemotherapy for Metastatic Colorectal Cancer Using Irinotecan
GIIRINALT	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	Palliative Chemotherapy for Metastatic Colorectal Cancer Using Weekly Irinotecan

CODE	Protocol	PPPO	Patient Handout	Protocol Title
GIPAJGEM	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	Adjuvant Chemotherapy for Pancreatic Cancer Using Gemcitabine
GIPGEM	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	Metastatic Cancer Of the Pancreas, Gallbladder or Bile Duct
GIRALT	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	Palliative chemotherapy for metastatic colorectal cancer using Raltitrexed in patients with previous Fluorouracil toxicity
UMYLENDEX	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Therapy of Multiple Myeloma Using Lenalidomide with Dexamethasone

REVISED PROTOCOLS, PPPOs AND PATIENT HANDOUTS (AFFECTED DOCUMENTS ARE CHECKED):

CODE	Protocol	PPPO	Patient Handout	Changes	Protocol Title
UBRAVABR	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>Eligibility clarified</i>	Palliative Therapy for Metastatic Breast Cancer using nanoparticle, albumin-bound (nab)-Paclitaxel (ABRAXANE®)
GIGAVECC	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>Requirement for CAP approval replaced by Class II indication</i>	Palliative Therapy for Metastatic or Locally Advanced Gastric or Esophagogastric Cancer Using Epirubicin, Cisplatin and Capecitabine
GIGAVECF	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>Requirement for CAP approval deleted</i>	Palliative Therapy for Metastatic or Locally Advanced Gastric, Esophagogastric Cancer Using Epirubicin, Cisplatin and Infusional 5-Fluorouracil
GOCXCRT	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>Return appointment clarified</i>	Treatment of High Risk Squamous Carcinoma, Adenocarcinoma, or Adenosquamous Carcinoma of the Cervix with Concurrent Cisplatin and Radiation
HNDE	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>Clarification of lab orders and premedication</i>	Therapy for Recurrent and Metastatic Nasopharyngeal Cancer using Cisplatin and Etoposide
HNLANPRT	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>Dose modifications for renal dysfunction and hematology clarified, frequency of clinical assessment added</i>	Treatment of Locally Advanced Nasopharyngeal Cancer with Concurrent Cisplatin and Radiation
HNM	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>Dose modifications for renal dysfunction and hematology clarified</i>	Head and Neck Cancer Using Methotrexate as Standard Therapy
LYHDMRP	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>Dose modifications for renal functions clarified</i>	Treatment of Primary Intracerebral Lymphoma with High Dose Methotrexate and Rituximab
LYHDMTXP	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>Dose modifications for renal functions clarified</i>	Treatment of Primary Intracerebral Lymphoma with High Dose Methotrexate
LYHDMTXR	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>Dose modifications for renal functions clarified</i>	Treatment of Leptomeningeal Lymphoma or Recurrent Intracerebral Lymphoma with High Dose Methotrexate

WEBSITE RESOURCES

The following are available on the BC Cancer Agency website (www.bccancer.bc.ca) under the Health Professionals Info section:

REIMBURSEMENT AND FORMS: BENEFIT DRUG LIST, CLASS II, COMPASSIONATE ACCESS PROGRAM (UNDESIGNATED INDICATION)	www.bccancer.bc.ca/HPI/ChemotherapyProtocols/Forms
CANCER DRUG MANUAL	www.bccancer.bc.ca/cdm
CANCER MANAGEMENT GUIDELINES	www.bccancer.bc.ca/CaMgmtGuidelines
CANCER CHEMOTHERAPY PROTOCOLS	www.bccancer.bc.ca/ChemoProtocols
CANCER CHEMOTHERAPY PRE-PRINTED ORDERS	www.bccancer.bc.ca/ChemoProtocols under the index page of each tumour site
SYSTEMIC THERAPY PROGRAM POLICIES	www.bccancer.bc.ca/HPI/ChemotherapyProtocols/Policies
UNCONVENTIONAL CANCER THERAPIES MANUAL	under Patient/Public Info, Unconventional Therapies

Editorial Review Board

Mário de Lemos, PharmD, MSc(Oncol) (Editor)
 Victoria Kyritsis, MSc (Clin Pharm) (Assistant Editor)
 Caroline Lohrisch, MD
 Johanna Den Duyf, MA

Judy Oliver, BScN, MEd
 Beth Morrison, MLS
 Jaya Venkatesh, MHA, CMA
 Susan Walisser, BSc (Pharm)

IN TOUCH	www.bccancer.bc.ca	bulletin@bccancer.bc.ca
BC CANCER AGENCY	(604) 877-6000	Toll-Free 1-(800) 663-3333
PROVINCIAL SYSTEMIC THERAPY PROGRAM	Ext 2247	atomash@bccancer.bc.ca
COMMUNITIES ONCOLOGY NETWORK	Ext 2744	jvenkate@bccancer.bc.ca
UPDATE EDITOR	Ext 2288	mdelemos@bccancer.bc.ca
COMMUNITIES ONCOLOGY NETWORK PHARMACIST	Ext 6277	laurelk@bccancer.bc.ca
COMMUNITIES ONCOLOGY NETWORK PHARMACY EDUCATORS...	www.bccancer.bc.ca/RS/CommunitiesOncologyNetwork/Educators/Pharmacists/cap_bcca@bccancer.bc.ca
COMPASSIONATE ACCESS PROGRAM OFFICE	Ext 6277	cap_bcca@bccancer.bc.ca
	Fax (604) 708-2026	
DRUG INFORMATION	Ext 6275	druginfo@bccancer.bc.ca
EDUCATION RESOURCE NURSE	Ext 2638	nursinged@bccancer.bc.ca
NURSING PROFESSIONAL PRACTICE	Ext 2623	ilundie@bccancer.bc.ca
LIBRARY/CANCER INFORMATION	1-(888)-675-8001	requests@bccancer.bc.ca
	Ext 8003	
OSCAR HELP DESK	1-(888)-355-0355	oscar@bccancer.bc.ca
	Fax (604) 708-2051	
PHARMACY PROFESSIONAL PRACTICE	Ext 2247	jkippen@bccancer.bc.ca
ABBOTSFORD CENTRE (AC)	(604) 851-4710	Toll-free: 1-(877) 547-3777
CENTRE FOR THE SOUTHERN INTERIOR (CCSI)	(250) 712-3900	Toll-Free 1-(888) 563-7773
FRASER VALLEY CENTRE (FVCC)	(604) 930-2098	Toll-Free 1-(800) 523-2885
VANCOUVER CENTRE (VCC)	(604) 877-6000	Toll-Free 1-(800) 663-3333
VANCOUVER ISLAND CENTRE (VICC)	(250) 519-5500	Toll-Free 1-(800) 670-3322